The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study
ObjectivesHip involvement is an important cause of disability and poor prognosis in patients with spondyloarthritis (SpA). Tumor necrosis factor (TNF)-α inhibitor treatment has been demonstrated to be effective in SpA patients with hip arthritis; however, quantitative assessment using MRI in long-te...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.740980/full |
| _version_ | 1818354030236139520 |
|---|---|
| author | Kui Zhang Kui Zhang Yan Zheng Yan Zheng Qing Han Qing Han Ying Liu Weitao Wang Weitao Wang Jin Ding Jin Ding Yan Wang Yan Wang Bei Zhang Bei Zhang Junfeng Jia Junfeng Jia Minwen Zheng Zhaohui Zheng Zhaohui Zheng Ping Zhu Ping Zhu |
| author_facet | Kui Zhang Kui Zhang Yan Zheng Yan Zheng Qing Han Qing Han Ying Liu Weitao Wang Weitao Wang Jin Ding Jin Ding Yan Wang Yan Wang Bei Zhang Bei Zhang Junfeng Jia Junfeng Jia Minwen Zheng Zhaohui Zheng Zhaohui Zheng Ping Zhu Ping Zhu |
| author_sort | Kui Zhang |
| collection | DOAJ |
| description | ObjectivesHip involvement is an important cause of disability and poor prognosis in patients with spondyloarthritis (SpA). Tumor necrosis factor (TNF)-α inhibitor treatment has been demonstrated to be effective in SpA patients with hip arthritis; however, quantitative assessment using MRI in long-term follow-up needs further application and observation.MethodsA total of 239 patients were involved in this study. Methotrexate and sulfasalazine were given as basic treatment. In total, 165 patients received TNF-α inhibitors plus basic treatment, and 74 received basic treatment only, as controls. Clinical symptoms were assessed at baseline and at weeks 12, 24, and 52. MRI performances of hip arthritis, including bone marrow edema (BME) and synovitis, were quantitatively assessed using the Hip Inflammation MRI Scoring System (HIMRISS).ResultsThe clinical values of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Harris hip score, and Ankylosing Spondylitis Disease Activity Score (ASDAS)-ESR in both groups showed significant clinical remission at week 52 (p < 0.001). However, the change in disease activity levels at week 52 in the control group was significantly worse than in the TNF-α inhibitor group. At week 52, MRI showed a significant remission trend in the TNF-α inhibitor group versus baseline, and total HIMRISS scores were significantly decreased (26.49 ± 10.37 vs. 20.59 ± 9.41, p < 0.001); the control group only had slight improvement (p < 0.05).ConclusionsTNF-α inhibitors could significantly improve clinical and MRI manifestations of hip involvement in patients with SpA. Quantitative MRI assessment combined with clinical assessment can be used to accurately evaluate the treatment effect of TNF-α in SpA patients with hip involvement to help guide targeted treatment. |
| first_indexed | 2024-12-13T19:18:56Z |
| format | Article |
| id | doaj.art-5a07f5dddba04d76a31f01a9be769a96 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-13T19:18:56Z |
| publishDate | 2021-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5a07f5dddba04d76a31f01a9be769a962022-12-21T23:34:13ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-09-011210.3389/fimmu.2021.740980740980The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical StudyKui Zhang0Kui Zhang1Yan Zheng2Yan Zheng3Qing Han4Qing Han5Ying Liu6Weitao Wang7Weitao Wang8Jin Ding9Jin Ding10Yan Wang11Yan Wang12Bei Zhang13Bei Zhang14Junfeng Jia15Junfeng Jia16Minwen Zheng17Zhaohui Zheng18Zhaohui Zheng19Ping Zhu20Ping Zhu21Department of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaDepartment of Radiology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaDepartment of Radiology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaDepartment of Clinical Immunology, Xijing Hospital, The Fourth Military Medical University, Xi’an, ChinaNational Translational Science Center for Molecular Medicine, Xi’an, ChinaObjectivesHip involvement is an important cause of disability and poor prognosis in patients with spondyloarthritis (SpA). Tumor necrosis factor (TNF)-α inhibitor treatment has been demonstrated to be effective in SpA patients with hip arthritis; however, quantitative assessment using MRI in long-term follow-up needs further application and observation.MethodsA total of 239 patients were involved in this study. Methotrexate and sulfasalazine were given as basic treatment. In total, 165 patients received TNF-α inhibitors plus basic treatment, and 74 received basic treatment only, as controls. Clinical symptoms were assessed at baseline and at weeks 12, 24, and 52. MRI performances of hip arthritis, including bone marrow edema (BME) and synovitis, were quantitatively assessed using the Hip Inflammation MRI Scoring System (HIMRISS).ResultsThe clinical values of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Harris hip score, and Ankylosing Spondylitis Disease Activity Score (ASDAS)-ESR in both groups showed significant clinical remission at week 52 (p < 0.001). However, the change in disease activity levels at week 52 in the control group was significantly worse than in the TNF-α inhibitor group. At week 52, MRI showed a significant remission trend in the TNF-α inhibitor group versus baseline, and total HIMRISS scores were significantly decreased (26.49 ± 10.37 vs. 20.59 ± 9.41, p < 0.001); the control group only had slight improvement (p < 0.05).ConclusionsTNF-α inhibitors could significantly improve clinical and MRI manifestations of hip involvement in patients with SpA. Quantitative MRI assessment combined with clinical assessment can be used to accurately evaluate the treatment effect of TNF-α in SpA patients with hip involvement to help guide targeted treatment.https://www.frontiersin.org/articles/10.3389/fimmu.2021.740980/fullMRIhipspondyloarthritisTNF-αASDAS-ESR |
| spellingShingle | Kui Zhang Kui Zhang Yan Zheng Yan Zheng Qing Han Qing Han Ying Liu Weitao Wang Weitao Wang Jin Ding Jin Ding Yan Wang Yan Wang Bei Zhang Bei Zhang Junfeng Jia Junfeng Jia Minwen Zheng Zhaohui Zheng Zhaohui Zheng Ping Zhu Ping Zhu The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study Frontiers in Immunology MRI hip spondyloarthritis TNF-α ASDAS-ESR |
| title | The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study |
| title_full | The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study |
| title_fullStr | The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study |
| title_full_unstemmed | The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study |
| title_short | The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study |
| title_sort | clinical and mri effect of tnf α inhibitors in spondyloarthritis patients with hip involvement a real world observational clinical study |
| topic | MRI hip spondyloarthritis TNF-α ASDAS-ESR |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.740980/full |
| work_keys_str_mv | AT kuizhang theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT kuizhang theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yanzheng theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yanzheng theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT qinghan theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT qinghan theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yingliu theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT weitaowang theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT weitaowang theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT jinding theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT jinding theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yanwang theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yanwang theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT beizhang theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT beizhang theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT junfengjia theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT junfengjia theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT minwenzheng theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT zhaohuizheng theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT zhaohuizheng theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT pingzhu theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT pingzhu theclinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT kuizhang clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT kuizhang clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yanzheng clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yanzheng clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT qinghan clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT qinghan clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yingliu clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT weitaowang clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT weitaowang clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT jinding clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT jinding clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yanwang clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT yanwang clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT beizhang clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT beizhang clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT junfengjia clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT junfengjia clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT minwenzheng clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT zhaohuizheng clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT zhaohuizheng clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT pingzhu clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy AT pingzhu clinicalandmrieffectoftnfainhibitorsinspondyloarthritispatientswithhipinvolvementarealworldobservationalclinicalstudy |